GLP-1 medications have revolutionized diabetes management and weight loss strategies, but to maximize their benefits, its essential to consider a healthy diet along with the treatment
The American College of Gastroenterology's 2021 guideline on irritable bowel syndrome management issued a conditional recommendation against the use of probiotics for global IBS symptoms, citing very low overall quality of evidence.[8] IBS is not the same as GLP-1 constipation, but it overlaps in terms of dysmotility-driven symptoms, and the guideline tone signals appropriate caution about probiotic claims in this neighborhood
Despite the robust body of evidence showing the cardiovascular benefits of GLP-1 RAs, their origins as diabetes/glucose medications and the mode of administration of all but one by subcutaneous injection have posed barriers for cardiologists to adopt them as a routine part of clinical practice
The most effective prevention strategy combines adequate protein intake (1.0-1.2 grams per kilogram daily), comprehensive micronutrient supplementation from day one, gradual dose titration to moderate the rate of weight loss, maintaining a caloric floor, and baseline blood work to identify and correct pre-existing deficiencies
These lower prices would make the discussion below less important
People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal conditions should avoid GLP1 weight-loss drugs unless specifically advised by their physician